A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects

Drug-Induced Liver Injury Clinical Trial

Official title:

A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in Treatment of Cholestatic and Mixed Drug Induced Liver Injury (DILI)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06019936
• Other study ID #: MT2004-II-C01
• Secondary ID: CTR20232066
• Status: Recruiting
• Phase: Phase 2
• Start date: August 10, 2023
• Est. completion date: October 10, 2025

Study information

• Verified date: August 2023
• Source: Shaanxi Micot Technology Limited Company
• Contact: LanLan Song, Master
• Phone: +8615929300901
• Email: songlanlan[@]micot.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI) subjects. The main questions it aims to answer are: 1. The Efficacy of MT2004 Capsule in Cholestatic and Mixed DILI subjects 2. The Safety and Pharmacokinetic characteristic of MT2004 Capsule in Cholestatic and Mixed DILI subjects 3. The mechanism of using MT2004 Capsule on Cholestatic and Mixed DILI subjects

Description:

Xi'An Aolitai Pharmaceutical Technology Co Ltd is developing MT2004, a novel investigational synthetic small molecule farnesoid X receptor (FXR) agonist targeted to the liver. The MT2004 was designed as the prodrug and the metabolites MT2004-met1 of MT2004 will act to the FXR receptor to regulate a series of genes expression. It also plays an important role in the metabolism of bile acids, lipids and sugars. The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI) subjects. The whole study will be divied to three stages including screening period (14 Days before the treatment), treatment period (the participants will be randomized to receive MT2004, or placebo orally (BID), for 12 weeks) and follow-up period. The study aims to recruit total of 80 subjects with Cholestatic and Mixed DILI, in which 12 of subjects will be firstly enrolled and allocated to the MT2004 group (Dose level: 25mg) as well as control group with the proportion of 2:1 by using the stratified randomization method. During the whole study, the adjustment of the subjects amount, the dose level as well as randomization proportion will based on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID. The placebo will be used in this study, and the researchers will compare the placebo and test article to see the safety and efficacy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: October 10, 2025
• Est. primary completion date: August 10, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1. 18= age = 75 years, male or female.

2. When diagnosis of acute DILI, the liver biochemical threshold of patients must meet one of the following criteria: :(1) ALT =5 ×ULN;(2) ALP =2× ULN;(3) ALT=3× ULN and TBil =2×ULN.

3. ALP =2× ULN, and conform to the clinical classification of cholestatic type or mixed type DILI in the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition) (cholestatic type: R value =2; Mixed type: 2<R value <5).

4. Excluded other common causes of acute liver injury, such as acute viral hepatitis A, B, C, E, autoimmune hepatitis, biliary tract disease, PBC, etc. (Exclusive diagnostic tests completed in our hospital or other hospitals after this suspected acute DILI event or within 2 months before screening were acceptable)

5. RUCAM causality scale score =6 points; If the RUCAM score is between the 3-5 it is necessary to evaluate the causal relationship by three experts according to the evaluation criteria of expert opinions in the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition), and at least two experts determine that the liver injury of the patients are "likely", "very likely" or "definitely" caused by drugs.

6. The serious level of DILI is within level 1-2 based on the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition).

7. The duration of this liver injury is less than 6 months.

8. The female with fertility must have had a negative pregnancy test results before being enrolled, or at least 1 year after pausimenia, or permanent sterilization =6 weeks(There should have a recording of hysterectomy, bilateral salpingo-oophorectomy). The female and their male partners with the fertility potential agree to utilize the effective contraceptive methods(the following two methods can be selected: 1. any of the condom, diaphragm, Sponge or Cervical Cap with with Spermicide ).

9. Fully understand the study process of the clinical trial, and provide the signed ICF of joinning the clinical trial.

Exclusion Criteria:

• 1. Acute or chronic liver failure or liver decompensation

2. The history of liver decompensation or portal hypertension history

3. Moderate or above renal insufficiency, creatinine clearance (Ccr) < 60mL/min (according to the MDRD formula).

4. Patients with serious diabetes and had poor control of blood sugar (HbA1c>10%)

5. Serious sysmetic diseases of cardiovascular, respiratory, neurological, urinary, digestive, and for any reason which, in the opinion of the Investigator think the subject is not suitable for participating in the study.

6. The predict survival period < 6 months.

7. Utilization of Perursodeoxycholic acid within 14 days before the treatment.

8. Utilization of S-adenosylmethionine within 1 days before the treatment.

9. The patients must regularly utilize the known strong CYP3A4/3A5 inhibitors such as Clarithromycin, Itraconazole, ketoconazole, Ritonavir, rifampicin, phenytoin, carbamazepine within 1 week before the treatment or for the whole study period.

10. Allergies or intolerances to study drug ingredients

11. Patients are under the gestation, lactation, or patients have the pregnancy planning during the study period and 90 days after the end of the clinical trial

12. Patients are not willing to ban the alcohol during the study period.

13. Patients had joined the other clinical trials within 3 months before the administration.

14. Other conditions that the investigator think the subject is not suitable for participating in the study.

Related Conditions & MeSH terms

• Chemical and Drug Induced Liver Injury
• Drug-Induced Liver Injury
• Wounds and Injuries

Intervention

Drug:
• MT2004 Capsule
The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
• MT2004 Capsule Placebo
The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.

Locations

Country	Name	City	State
China	Shanghai Jiaotong University School of Medicine,Renji Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Xi'An Aolitai Pharmaceutical Technology Co Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety endpoint	Adverse Events(AEs) will be recorded and evaluated for their seriousness, severity, and relationship to the study drug.	From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 12 weeks.
Primary	Primary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the decreasing rate on serum ALP compared to baseline.	On the week 4 after the administration
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the decreasing rate on ALP compared to baseline.	On the week 2,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the percentage of patients whose ALP decreased by more than 15% from baseline.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the recovery rate of ALP.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the decreasing rate on GGT compared to baseline.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the recovery rate of GGT.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the decreasing rate on ALT compared to baseline.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the recovery rate of ALT.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the decreasing rate on AST compared to baseline.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the recovery rate of AST.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the decreasing rate on TBIL compared to baseline.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the decreasing rate on TBA compared to baseline.	On the week 2,4,8,12 after the administration and the week 4 follow-up period
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the area of serum ALP decreasing rate-time curve.	On the week 2,4,8,12 after the administration
Secondary	Secondary efficacy endpoint	The efficacy of MT2004 will be evaluated based on the percentage of patients developed to DILI level 3-4 after the administration.	On the week 2,4,8,12 after the administration and the week 4 follow-up period